Stock Market Today: Stocks Soar on Apple Buyback News, Jobs Data
The main indexes rallied hard to end the week thanks to Apple's $110 billion stock repurchase plan and a big April payrolls miss.
Stocks jumped out of the gate Friday and never looked back. Sentiment got a major lift thanks to a positive reaction to Apple's (AAPL) quarterly earnings report and a bad-news-is-good-news jobs report.
The excitement got started late Thursday when Apple reported higher-than-expected earnings and revenue for its fiscal second quarter. The iPhone maker also unveiled a record $110 billion stock buyback program and its 12th straight annual dividend hike.
"We believe these results appear to change the narrative on the AAPL story, as China is holding up better than expected and there are a host of upcoming events and catalysts on the horizon that could improve investor sentiment and drive consensus estimates higher," says CFRA Research analyst Angelo Zino, who maintained a Buy rating on Apple after earnings.
From just $107.88 $24.99 for Kiplinger Personal Finance
Become a smarter, better informed investor. Subscribe from just $107.88 $24.99, plus get up to 4 Special Issues
Sign up for Kiplinger’s Free Newsletters
Profit and prosper with the best of expert advice on investing, taxes, retirement, personal finance and more - straight to your e-mail.
Profit and prosper with the best of expert advice - straight to your e-mail.
One of those events occurs next Tuesday, May 7, when Apple is expected to unveil new iPads for the first time in two years.
Amgen rallies after earnings, weight-loss drug news
Apple stock surged 6.0% after earnings, but it was far from the best Dow Jones stock today. Rather, that title went to Amgen (AMGN), which spiked 11.8% after its earnings report.
The drugmaker reported earnings of $3.96 per share on $7.45 billion in revenue, more than analysts expected. More notable was news Amgen is discontinuing the development of its weight-loss pill and instead preparing for a Phase III study of its obesity injectable, MariTide. Amgen executives said Phase II data for the weight-loss drug is encouraging and will be released later this year.
"While we appreciate there is still plenty of work ahead (full Phase II data, starting Phase III, etc.), the reality is AMGN probably has a 'monthly' drug on their hands and can be a $5 billion to $10 billion-plus player in the future," says Jefferies analyst Michael Yee (Buy). "This should drive a re-rating of the stock as it remains very under-owned across the Street."
Jobs report shows wage growth cools
On the economic front, investors were busy dissecting the April jobs report. Data from the Bureau of Labor Statistics showed the U.S. added 175,000 new jobs in April, the smallest increase in six months. The unemployment rate edged up to 3.9% from 3.8% and average hourly earnings – a measure of inflation – rose 3.9% year-over-year vs March's 4.1% increase.
"In an environment where the market is worried about inflation, a softer jobs report with (slightly) higher unemployment, lower-than-expected wage growth and job creation shows that inflation pressure from wages is easing," says Chris Zaccarelli, chief investment officer for Independent Advisor Alliance.
Following Federal Reserve Chair Jerome Powell's press conference this week where he indicated more rate hikes were unlikely, "the market is back to risk-on mode as long as the Fed maintains an easing bias," Zaccarelli adds.
Indeed, at the close, the Dow Jones Industrial Average was up 1.2% at 38,675, the S&P 500 was 1.3% higher at 5,127, and the Nasdaq Composite had gained 2.0% to 16,156.
Related content
- Kiplinger's Economic Calendar for This Week
- Philips CPAP Settlement: What to Know
- How the Biden Marijuana Shift Could Impact Taxes
Profit and prosper with the best of Kiplinger's advice on investing, taxes, retirement, personal finance and much more. Delivered daily. Enter your email in the box and click Sign Me Up.

With over a decade of experience writing about the stock market, Karee Venema is the senior investing editor at Kiplinger.com. She joined the publication in April 2021 after 10 years of working as an investing writer and columnist at a local investment research firm. In her previous role, Karee focused primarily on options trading, as well as technical, fundamental and sentiment analysis.
-
Fed's Rate Cuts Could Have Impacts You Might Not AnticipateUnderstanding how lower interest rates could impact your wallet can help you determine the right financial moves to make.
-
Past Performance Is Not Indicative of Your Adviser's ExpertiseMany people find a financial adviser by searching online or asking for referrals from friends or family. This can actually end up costing you big-time.
-
I'm want to give my 3 grandkids $5K each for Christmas.You're comfortably retired and want to give your grandkids a big Christmas check, but their parents are worried they might spend it all. We ask the pros for help.
-
Past Performance Is Not Indicative of Your Financial Adviser's ExpertiseMany people find a financial adviser by searching online or asking for referrals from friends or family. This can actually end up costing you big-time.
-
I'm a Financial Planner: If You're Not Doing Roth Conversions, You Need to Read ThisRoth conversions and other Roth strategies can be complex, but don't dismiss these tax planning tools outright. They could really work for you and your heirs.
-
Could Traditional Retirement Expectations Be Killing Us? A Retirement Psychologist Makes the CaseA retirement psychologist makes the case: A fulfilling retirement begins with a blueprint for living, rather than simply the accumulation of a large nest egg.
-
I'm a Financial Adviser: This Is How You Can Adapt to Social Security UncertaintyRather than letting the unknowns make you anxious, focus on building a flexible income strategy that can adapt to possible future Social Security changes.
-
I'm a Financial Planner for Millionaires: Here's How to Give Your Kids Cash Gifts Without Triggering IRS PaperworkMost people can gift large sums without paying tax or filing a return, especially by structuring gifts across two tax years or splitting gifts with a spouse.
-
'Boomer Candy' Investments Might Seem Sweet, But They Can Have a Sour AftertasteProducts such as index annuities, structured notes and buffered ETFs might seem appealing, but sometimes they can rob you of flexibility and trap your capital.
-
AI Stocks Lead Nasdaq's 398-Point Nosedive: Stock Market TodayThe major stock market indexes do not yet reflect the bullish tendencies of sector rotation and broadening participation.
-
Got $100 to Gamble? These Penny Stocks Could Be Worth the RideVolatile penny stocks are high-risk plays with potentially high rewards. If you have $100 you can afford to lose, these three names are worth a look.